|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Methyldopa#Overdosage]] |
| {{Methyldopa}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==OVERDOSAGE==
| |
| | |
| Acute overdosage may produce acute [[hypotension ]]with other responses attributable to brain and gastrointestinal malfunction (excessive [[sedation]], weakness, [[bradycardia]], [[dizziness]], light-headedness, [[constipation]], [[distention]], [[flatus]], [[diarrhea]], [[nausea]], [[vomiting]]).
| |
| | |
| In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or [[emesis ]]may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion. Otherwise, management includes special attention to cardiac rate and output, blood volume, electrolyte balance, [[paralytic ileus]], urinary function and cerebral activity.
| |
| | |
| Sympathomimetic drugs [e.g., [[levarterenol]], [[epinephrine]], ARAMINE®1 ([[Metaraminol ]]Bitartrate)] may be indicated. Methyldopa is [[dialyzable]].
| |
| | |
| The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat.
| |
| | |
| <sup>1</sup>
| |
| | |
| ARAMINE® is a registered trademark of Merck.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPA TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87d63fd-48f7-4130-af03-5e263c338fe4 | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |